CTNM

Business Context and Reporting Period

Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A clinical-stage biopharmaceutical company developing small molecule therapies for inflammatory and fibrotic diseases. The Company operates as a single reportable segment and is classified as an emerging growth company and smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased by $0.9 million (5.5%) for the three months and $2.4 million (7.6%) for the six months ended June 30, 2026, compared to the same periods in 2025.
• R&D Expenses: R&D expenses decreased by $1.4 million (quarterly) and $3.4 million (six-month) year-over-year. This reduction was primarily driven by lower contract research organization (CRO) costs due to the completion of the VISTA Phase 2 trial for PIPE-307 and the Phase 1b PET trial for PIPE-791. These decreases were partially offset by a $3.1 million increase in costs for the ongoing Phase 2 trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF).
• G&A Expenses: G&A expenses increased by $0.9 million (quarterly) and $1.8 million (six-month) year-over-year, primarily due to higher stock-based compensation and personnel-related expenses.
• Interest Income: Increased by $0.3 million (quarterly) and $0.6 million (six-month) due to higher funds invested in marketable securities.
• Liquidity Position: Cash and cash equivalents decreased from $75.6 million at December 31, 2025, to $14.7 million at June 30, 2026, while marketable securities increased from $187.3 million to $221.8 million. Total liquid assets remain at $236.6 million.

Guidance, Outlook, and Risks

• Clinical Progress:
  • PIPE-791 (IPF): Patient dosing initiated in the PROPEL-IPF Phase 2 trial (approx. 324 patients) in Q1 2026. Over 50 sites activated.
  • PIPE-791 (Chronic Pain): Positive topline data announced in April 2026 from a Phase 1b trial, demonstrating favorable safety and encouraging efficacy trends.
  • PIPE-307 (Depression): Partnered with J&J. J&J completed enrollment (107 participants) for the Phase 2 Moonlight-1 trial in June 2026.
  • CTX-343: Development deferred until specific funding is obtained.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($236.6 million) are sufficient to fund operations for at least 12 months from the filing date.
• Capital Resources: The Company maintains an "at-the-market" (ATM) sales agreement with Leerink Partners, amended in March 2026 to allow sales of up to $100.0 million in aggregate. No shares were sold under this program in the first half of 2026. A follow-on public offering in December 2025 raised $93.0 million.
• Key Risks:
  • Manufacturing Dependency: Reliance on third-party Contract Manufacturing Organizations (CMOs), specifically WuXi AppTec for PIPE-791. WuXi AppTec was designated on the U.S. Department of Defense's 1260H List on June 8, 2026. While grandfathering provisions currently apply under the BIOSECURE Act, future restrictions could necessitate a costly and time-consuming transition to a new CMO.
  • Regulatory & Clinical Uncertainty: No products are approved; success depends on clinical trial outcomes and regulatory approvals.
  • Financing Needs: Future funding requirements may necessitate equity or debt financing, potentially resulting in dilution or restrictive covenants.

Investor Verification Checklist

• Manufacturing Risk: Verify the status of WuXi AppTec regarding the BIOSECURE Act and the Company's contingency plans for transitioning manufacturing if restrictions tighten.
• Cash Burn Rate: Confirm the sustainability of the $236.6 million cash position against the projected increase in operating expenses as the Phase 2 IPF trial progresses.
• PIPE-791 Trial Data: Monitor upcoming data readouts from the PROPEL-IPF Phase 2 trial and the chronic pain Phase 1b trial for efficacy signals.
• PIPE-307 Partnership: Track J&J's progress in the Moonlight-1 Phase 2 trial for depression, as this is a key potential revenue driver via milestones and royalties.
• Capital Raising: Assess the Company's ability to raise additional capital if the 12-month runway proves insufficient or if clinical results necessitate accelerated development.